A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Participants With Guillain-Barré Syndrome (GBS)

Sponsor

Hoffmann-La Roche (Industry)

Overall Status

Not yet recruiting

CT.gov ID

NCT05494619

Collaborator

Chugai Pharmaceutical Co., Ltd. (Sponsor in Taiwan and Japan) (Other)

154

Enrollment

Arms

47.8

Anticipated Duration (Months)

Study Details

Study Description

Brief Summary

The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of crovalimab compared with placebo as an add-on therapy to intravenous immunoglobulin (IVIg) in participants with severe GBS.

Condition or Disease	Intervention/Treatment	Phase
Guillain-Barré Syndrome	Drug: Crovalimab Drug: Placebo Drug: Intravenous immunoglobulin therapy	Phase 3

Study Design

Study Type:

Interventional

Anticipated Enrollment :

154 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

Double (Participant, Investigator)

Primary Purpose:

Treatment

Official Title:

A Phase III Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Patients With Guillain-Barré Syndrome

Anticipated Study Start Date :

Oct 5, 2022

Anticipated Primary Completion Date :

Mar 19, 2026

Anticipated Study Completion Date :

Sep 30, 2026

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Crovalimab Participants will receive a single intravenous (IV) infusion of crovalimab on Day 1 based on body weight, followed by crovalimab subcutaneous (SC) injection on Days 2, 8, 15, and 22 for a total of 4 weeks. Additionally, intravenous immunoglobulin (IVIg) background therapy will be administered once a day (QD) for 5 days.	Drug: Crovalimab Crovalimab will be administered at a dose of 1000 milligrams (mg) IV (for participants with body weight ≥ 40 kilograms (kg) and <100 kg) or 1500 mg IV (for participants with body weight ≥ 100 kg) on Day 1, followed by crovalimab 340 mg SC injections on Days 2, 8, 15 and 22 in all participants. Drug: Intravenous immunoglobulin therapy All participants will receive background therapy of IVIg at a dose of 400 milligrams/kilograms (mg/kg) QD for 5 days.
Placebo Comparator: Placebo Participants will receive a single IV infusion of placebo on Day 1 based on body weight, followed by placebo SC injections on Days 2, 8, 15, and 22 for a total of 4 weeks. Additionally, IVIg background therapy will be administered QD for 5 days.	Drug: Placebo Placebo will be administered IV on Day 1 at a dose of 1000 mg for participants with body weight ≥ 40 kg to < 100 kg, or 1500 mg for participants with body weight ≥ 100 kg. It will be administered SC on Days 2, 8, 15, and 22 at a dose 340 mg in all participants. Drug: Intravenous immunoglobulin therapy All participants will receive background therapy of IVIg at a dose of 400 milligrams/kilograms (mg/kg) QD for 5 days.

Arm

Intervention/Treatment

Experimental: Crovalimab

Participants will receive a single intravenous (IV) infusion of crovalimab on Day 1 based on body weight, followed by crovalimab subcutaneous (SC) injection on Days 2, 8, 15, and 22 for a total of 4 weeks. Additionally, intravenous immunoglobulin (IVIg) background therapy will be administered once a day (QD) for 5 days.

Drug: Crovalimab

Crovalimab will be administered at a dose of 1000 milligrams (mg) IV (for participants with body weight ≥ 40 kilograms (kg) and <100 kg) or 1500 mg IV (for participants with body weight ≥ 100 kg) on Day 1, followed by crovalimab 340 mg SC injections on Days 2, 8, 15 and 22 in all participants.

Drug: Intravenous immunoglobulin therapy

All participants will receive background therapy of IVIg at a dose of 400 milligrams/kilograms (mg/kg) QD for 5 days.

Placebo Comparator: Placebo

Participants will receive a single IV infusion of placebo on Day 1 based on body weight, followed by placebo SC injections on Days 2, 8, 15, and 22 for a total of 4 weeks. Additionally, IVIg background therapy will be administered QD for 5 days.

Drug: Placebo

Placebo will be administered IV on Day 1 at a dose of 1000 mg for participants with body weight ≥ 40 kg to < 100 kg, or 1500 mg for participants with body weight ≥ 100 kg. It will be administered SC on Days 2, 8, 15, and 22 at a dose 340 mg in all participants.

Drug: Intravenous immunoglobulin therapy

All participants will receive background therapy of IVIg at a dose of 400 milligrams/kilograms (mg/kg) QD for 5 days.

Outcome Measures

Primary Outcome Measures

Percentage of Participants who Reach Hughes Functional Grade (FG) Score ≤ 1 on the Guillain-Barré Syndrome Disability Scale (GBS-DS) at Week 24 [Week 24]
The Guillain-Barré Syndrome disability score (GBS DS) is used to assess the degree of functional disability of study participants. The scale consists of seven grades of functional disability ranging from 0 (healthy with no symptoms attributable to GBS) to 6 (death).

Secondary Outcome Measures

Time to Recover Independent Walking Assessed Using the 10-Meter Walk Test (10-MW) [Up to approximately 52 weeks]
Defined as time from randomization to the first time point at which the participant is able to walk independently, assessed using the 10-MWT.
Functional Outcome on GBS-DS at Week 8 [Week 8]
Percentage of Inflammatory Rasch-Built Overall Disability Scale (I-RODS) Responders at Week 24 [Week 24]
Defined as a participant who is able to perform all activities assessed by the I-RODS with or without some difficulties (graded 1 or 2). I-RODs is a 24-item scale to rate a participant's general ability to function and complete activities of daily living. The items range in difficulty from very easy ("reading a newspaper/book" and "eating") to very difficult ("standing for hours" and "running"). The participant assigns a score between 0 and 3 (0: not possible, 1: possible with difficulty, 2: possible without any difficulty, 3: unable to perform before GBS [option 3 only available at the baseline visit]) to each item.
Mean Post-Recovery Time [Randomization to Week 24]
Defined as the time from reaching FG ≤ 1 for the first time after randomization to Week 24
Duration of Ventilator Support [Randomization to Week 24]
Percentage of Participants with Treatment Emergent Adverse Events [Up to approximately 52 weeks]
Adverse events severity was determined according to National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (NCI CTCAE v5.0) grading
Percentage of Participants with Treatment Emergent Adverse Events Leading to Study Drug Discontinuation [Up to approximately 52 weeks]
Percentage of Participants with Anti-Drug Antibodies to Crovalimab [Up to approximately 52 weeks]
Serum Concentrations of Crovalimab [From Day 1 up to Week 52]

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Body weight >= 40 kg at screening
Confirmed diagnosis of GBS according to National Institute of Neurological Disorders and Stroke (NINDS) classification system
Onset of weakness due to GBS within 2 weeks before randomization
Able to start the first dose of blinded study drug within 2 weeks of onset of weakness
Able to climb a flight of stairs prior to GBS
Unable to walk independently for >=10 meters (FG >=3) with deteriorating weakness as per investigator judgment, or FG 4 or FG 5 on the GBS-DS. These criteria must be satisfied during screening.
Undergoing or starting IVIg treatment (400 mg/kg QD for 5 days) prior to first blinded study drug administration. Participants must be able to receive the first dose of blinded study drug before the final dose of IVIg during the 5-day period of IVIg treatment.
A record of vaccination (<=3 years) against Neisseria meningitidis, Haemophilus influenzae type B, and Streptococcus pneumonia prior to initiation of blinded study drug, in accordance with most current local guidelines as applicable for patients with complement deficiency.
Adequate hepatic and renal function
For female participants of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraception during the treatment period and for up to 11 months after the final dose of study treatment.

Exclusion Criteria:

Clear clinical and historical evidence of significant or disabling acute or chronic peripheral neuropathy of alternative etiology, chronic inflammatory demyelinating polyneuropathy, severe vitamin deficiency, porphyria, or diagnosis of Charcot Marie Tooth disease or other genetic neuropathy
History of requiring a permanent aid to walk prior to GBS
Treatment with plasmapheresis or PLEX after GBS diagnosis, or a plan to receive this treatment
Receipt of systemic immunosuppressive treatment within 4 weeks prior to randomization
Known or suspected hereditary complement deficiency
Known or suspected immune deficiency
Recent use (up to five half-lives) of treatment with complement inhibitors (e.g., 10 weeks for eculizumab, 41 weeks for ravulizumab)
History of Neisseria meningitidis infection within 12 months prior to screening and up to first blinded study drug administration (Day 1)
Contraindication that would prevent use of any class of antibiotics as Neisseria meningitides prophylaxis
Immunization with a live attenuated vaccine within 1 month before first blinded study drug administration (Day 1)
Participants who have been partially or fully vaccinated against SARS-CoV-2 with a locally approved vaccine are eligible to be enrolled in the study, 3 days or longer after inoculation.
Recent SARS-CoV-2 infection (defined by a positive PCR test within the 2-week period prior to screening), or ongoing symptoms of active COVID-19
Any systemic bacterial, viral, or fungal infection ongoing at screening and up to the first blinded study drug administration (Day 1) which, in the investigators' judgment, is active and could potentially be worsened by immunosuppression
Current hepatitis B, hepatitis C, or HIV infection
History of malignancy within 5 years prior to screening and up to the first blinded study drug administration (Day 1)
History of hypersensitivity, allergic, or anaphylactic reactions to crovalimab or IVIg, including hypersensitivity to human, humanized, or murine monoclonal antibodies, or known hypersensitivity to any constituent of the products
For participants with prior exposure to anti-CD20 agents, most recent anti-CD20 treatment within 6 months prior to screening
Substance abuse within 12 months prior to screening, in the investigator's judgment
Active suicidal ideation within 6 months prior to screening or history of suicide attempt within 3 years prior to screening
Concurrent disease, treatment, procedure or surgery, or abnormality in clinical laboratory tests that could interfere with the conduct of the study, may pose any additional risk for the patient, or would, in the opinion of the investigator, preclude the patient's safe participation in and completion of the study
Participation in another interventional treatment study with an investigational agent or use of any experimental therapy within 28 days of screening or within five half-lives of that investigational product, whichever is longer
Splenectomy <= 6 months prior to screening
Selective IgA deficiency with development of antibodies to IgA
Only applicable for participants receiving proline-containing IVIg products: History or ongoing hyperprolinaemia type I or II at screening
Only applicable for participants receiving sucrose/glucose/maltose-containing IVIg products: History of or ongoing diabetes mellitus or use of concomitant nephrotoxic medications
Pregnancy or breastfeeding, or intention of becoming pregnant during the study or within 11 months after the final dose of crovalimab.